The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome.


No votes yet
 
Related
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the future construction of a new manufacturing plant for the active substance...
3 min
05/09/2019
Operating revenue increased by 21% to 177.5 million euros in the first half of 2019, mainly driven by the strength of the specialty...
6 min
30/07/2019